the fda regulatory & compliance symposium

Real people. Real results.®

N o r t h A m e r I c a • E u r o p e • A s I a / P a c I f I c • L a t I n A m e r I c a • A f r I c a

The FDA Regulatory & Compliance Symposium

Managing Risks – From Pipeline to Patient

August 24-26, 2005

cGMP Good for Business But Who is Enforcing Who?

Presented By: Anthony C. Celeste

Senior Vice President

Kendle/AAC

August 25, 2005

Why GMPs?

• Historical Perspective

– Early concepts

– Development of GMP concept(s)

• Legislative Mandate 1962

– Regulation development

– June 1963

– 1968 “Intensified Drug Inspection Program”

– January 1971 Federal Register (Final Regulations)

– September 1978 umbrella cGMP Regulations

Industry View of GMPs

– FDA Inconsistency

– Investigator expertise

– “Level the playing field”

GMP Benefits to Industry

– Good business practices

– Build in quality

• Enhance reputation

• Cut compliance costs

• Overall savings

• Avoidance of problems and bad publicity

FDA Enforcement Statistics

• Summary of FDA Actions/Activities

– 1999 - 2003

Source of Data: Recall Operations Staff, Division of Compliance

Management and Operations, Office of Enforcement, HFC-210

Recalls = Products Recalled [Center Classification Determined by Product Type]Description

Description

Source of Data: Program Evaluation Branch, DPEM, Office of Resource Management, HFC-42Note: Does not include Office of Criminal Investigations data.

Description

Source of Data: Program Evaluation Branch, DPEM, Office of Resource Management, HFC-42 Note: Does not include Office of Criminal Investigations data.

Description

Source of Data: Division of Compliance Management and Operations, Office of Enforcement, HFC-210

Source of Data: Recall Operations Staff, Division of Compliance Management and Operations, Office of Enforcement, HFC-210

Description

Source of Data: Recall Operations Staff, Division of Compliance Management and Operations, Office of Enforcement, HFC-210

Description

FDA Actions

– Significance of numbers?

– Risk Management

– Changing role of GMPs

– cGMPs for the 21st century

• Probability of occurrence of harm and the severity of that harm

– Includes concepts of “hazard” and “exposure”

• What is the relevant “harm”?

– Unsafe or ineffective drugs

– Reduction in safety/effectiveness

• Clinically significant

– Reduction in drug quality

Risk Management

• “Systematic application of management policies, procedures and practices to the tasks of analyzing, evaluating and controlling risk”

ISO 14971, Sections 2.13 and 2.18

Risk Management

• Risk Assessment

– Relationship between process knowledge and process risk

Risk Management

• Risk Control

– Option analysis

• Corrective and preventive actions

– Prioritize

– Implementation

– Residual risk evaluation

– Overall risk evaluation

Risk Management

• Post-Production Information

– Post-production experience

– Review of risk management experience

Risk Assessment

• An assessment of the product to determine:

– The probability of occurrence of harm from someone using your product

– The consequences of that harm and how severe it may be

Risk Management

• Major Themes

– Focus cGMP requirements on public health risks

– Ensure FDA’s essential work does not impede innovation by industry

– Enhance the consistency and predictability of FDA’s approach

– Relevance of risk management to compliance activities

Elements Impacting FDA Inspections

• cGMP Inspections

– Work planning (address risks)

– Investigator qualifications

• Communication of Findings

– Evaluate Warning Letters and FDA-483s

– Dispute Resolution

• Rollback of 21 CFR Part 11

• Encourage Best Practices

– Process Analytical Technology (PAT)

CDER Compliance Public Health Mission

• CDER has stated that its primary mission is ensuring that safe and effective drugs are available to the American public.

• CDER’s Office of Compliance advances CDER’s mission primarily by protecting Americans from unsafe or ineffective drugs.

Pharmaceutical GMPs for the 21st Century

• February 20, 2003, FDA provided a progress report on various aspects of its GMP initiative, Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach.

– Integrating a risk-based approach applies to all aspects of the initiative, including various aspects of the GMP inspection programs.

What They Look At: Focus of FDA’s Inspection

• Revise compliance programs to implement risk-based targeting

– Focus inspection on areas most likely to uncover GMP deviations with greatest public health significance

– Statistically-based auditing for areas not known to be high risk

What They Look At: Focus of FDA’s Inspection

• Use risk assessment tools in evaluating significance of GMP deviations for further regulatory action

• Account for potential failures in a process – “Quality by Design”

• “Corrective and Preventive Actions”

• One very effective way of managing risk

Industry’s Role

• Participation with FDA

• Innovation and technical advances

• Quality management

Participation with FDA

• Provide review, comment on guidelines and proposals

– Critical Path Initiative

– PAT

• Participate in committee deliberations (PDA, ISPE, Pharma, etc.)

• Training FDA Investigators/Reviewers

Innovation and Technical Advances

• Share research and development initiatives in manufacturing

• Work with FDA on technical improvements

• Process Analytical Technology

Quality Management

• Who is management?

• Results of poor management

• Proactive system(s)

Who is Management

• Level in organization that is responsible for:

– Hiring and firing, especially in quality area

– Organize and respond to audit and inspection findings

– Control availability of resources dollars and personnel.

Management Responsibilities

• Assure employee training and understanding

• Implement and document corrective actions

• Assure proper communications and decision making

Results of Poor Management

• Lack of adequately qualified and well trained employees

• Poor quality systems in place

• Non-conforming manufactured products (GMPs)

Penalties for Non-Compliance• FDA action

• Company’s reputation

• Effect on business

Lessons Learned

• Those who cannot remember the past are doomed to repeat it.

• But the real challenge is quantifying the past for commitment to memory.

• If some is GOOD – more is BETTER.

the fda regulatory & compliance symposium

Documents

fda regulatory perspective: data integrity

the fda regulatory and compliance symposium managing risks...

fda regulatory & compliance symposium cambridge, august 26,...

pierce's disease fda regulatory framework - gabriel paulino...

introduction to us fda regulatory framework

fda regulatory and compliance symposium

2007 drug and device fraud issues prosecuting drug and...

drug safety and fda “revitalization” legislation dan...

fda method development and regulatory application in ... ·...

fda perspective: scientific and regulatory issues … ·...

fda s office of regulatory affairs aligns for the …...fda...

regulatory background and past fda approvals in colorectal...

p130004 resure sealant - fda regulatory consulting and

regulatory authorities (us-fda, who and ich)

the fda regulatory and compliance symposium managing risks...

regulatory consideration for biosimilars by fda

overview of the fda: history, regulatory … - fda...

cms data and price information collection: what are the...

inspection by regulatory authority ( fda )

fda regulatory compliance reconsidered